A Phase 3 interventional study of GWP42003-P in Rett Syndrome and RTT, sponsored by Jazz Pharmaceuticals. Terminated at 31 sites in 6 countries. Open to participants aged 2 Years to 18 Years. Per ClinicalTrials.gov, last updated 2022-08-08.
Sponsored by Jazz Pharmaceuticals · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 55 studies in Rett Syndrome with a site in United States — 11 open to participants now, 21 under way, 5 of them phase 3. Rett Syndrome · United States.
Among the 55 studies in Rett Syndrome with a site in United States, this one is the 22nd largest by enrollment of the 34 interventional ones that give a count, is one of 4 that started in 2020, is one of 11 in phase 3, and was the 29th registered.
96 studies on the registry are indexed under Rett Syndrome; 19 are open to participants now.
Browse Rett Syndrome studies →11 of the 55 studies in Rett Syndrome with a site in United States are open now. Recruiting first, the newest first:
Biomed Industries, Inc. · Sites in United States, Australia
Ages 5–20 · Women only
UCB BIOSCIENCES, Inc. · Sites in United States, Belgium, France and 9 more countries
Ages 5–35
University of Rochester · Sites in United States
Ages 2+ · Healthy volunteers
University of Minnesota · Sites in United States
Ages 18–99
Ionis Pharmaceuticals, Inc. · Sites in United States, Austria, Canada and 2 more countries
Ages 2–65 · Men only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 14 Rett Syndrome studies recruiting now, 4 (29%) set no upper age limit and 7 (50%) stop at 75 or younger; 12 take children under 18; 3 take healthy volunteers.
This study: 2 Years to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
55 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 15 · Phase 3 14
First in 2004; this study’s year is marked. 4 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 21 is below the median of 30 across 64 interventional studies indexed under Rett Syndrome.
Median enrollment 32 across the 34 interventional studies, 146 across the 21 observational. Of the 31 that completed or were terminated, 14 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 55 have an industry lead sponsor. The 10 most frequent:
Jazz Pharmaceuticals is the lead sponsor of 173 studies on the registry; 18 are open to participants now.
Of its 42 completed or terminated interventional studies of FDA-regulated products, 32 (76%) have results posted.
Jazz Pharmaceuticals has 2 studies filed under Rett Syndrome — fewer than ten, so there is no comparison to draw.
10 of the studies in Rett Syndrome with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06840496Phase 3Biomed Industries, Inc.To Investigate the Efficacy of Treatment With Oral NA-921 (Bionetide) Versus Placebo in Females With Rett Syndrome | 2027-09-30 |
| NCT06338267Rett Syndrome Research TrustValidating Innovative Biosensors for Rett Autonomic Symptom Tracking | 2026-11 |
| NCT03655223RTI InternationalEarly Check: Expanded Screening in Newborns | 2026-11-30 |
| NCT06139172Rush University Medical CenterWeb Intervention for Parents of Youth With Genetic Syndromes (WINGS) | 2026-12 |
| NCT05012475Georgetown UniversityMeasuring Impact of Computer Gaming on Arm Use in Rett Syndrome | 2026-12-31 |
Add all 10 to your calendar (.ics) → With an account.
Among the 55 studies in Rett Syndrome with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will be conducted to evaluate the long-term safety of cannabidiol oral solution (GWP42003-P, CBD-OS) in participants with Rett syndrome.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
100 milligrams per milliliter (mg/mL) GWP42003-P oral solution, taken twice daily (morning and evening).
Drug: GWP42003-P
GWP42003-P presented as an oral solution containing cannabidiol in the excipients sesame oil with anhydrous ethanol, sweetener (sucralose), and strawberry flavoring
Also known as: Cannabidiol, CBD, Epidiolex, CBD-OS
Number of Participants With Any Treatment-emergent Adverse Events (TEAEs), Discontinuations Due to AEs, Serious AEs, and Treatment-related AEs
Adverse events (AEs) were defined as any new unfavorable/unintended signs/symptoms (including abnormal laboratory findings when relevant) or diagnosis or worsening of a pre-existing condition that occurs during the study. TEAEs were defined as the AEs that started or worsened in severity or seriousness following the first dose of GWP42003-P. A serious AE was defined as any AE that results in any of the following outcomes: death, life-threatening adverse experience, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or cancer, any other experience that suggests a significant hazard, contraindication, side effect or precaution that may require medical or surgical intervention to prevent one of the outcomes listed above, or an event that changes the risk/benefit ratio of the study.
Time frame: Baseline of randomized controlled trial (RCT) Visit 1 (Day 1) up to Visit 16 (Day 767) in the OLE
Number of Participants With Treatment-emergent Clinical Laboratory Parameters From the Baseline at Any Time Post-dose
Treatment-emergent clinical parameters were defined as the following: Treatment-emergent alanine transferase (ALT) \> 3×upper limit of normal (ULN), \> 5×ULN and \> 8×ULN; Treatment-emergent aspartate aminotransferase (AST) \> 3×ULN, \> 5×ULN and \> 8×ULN; Treatment-emergent ALT or AST \> 3×ULN, \> 5×ULN and \> 8×ULN; Treatment-emergent ALT or AST \> 3×ULN and either bilirubin \> 2×ULN or international normalized ratio (INR) \> 1.5.
Time frame: Baseline of randomized controlled trial (RCT) Visit 1 (Day 1) up to Visit 14 (Day 729) in the OLE
Number of Participants With Potentially Clinically Significant Changes in Vital Sign Values of Blood Pressure From the Baseline at Any Time Post-dose
Potentially clinically significant vital sign values of blood pressure (BP) were defined as sitting systolic BP (mmHg) change: \< -20 or \> 20 mmHg and sitting diastolic BP change: \< -10 or \> 10 mmHg. Vital sign measurements were taken in a sitting position at rest for 5 minutes. Blood pressure readings were recorded using the same arm throughout the trial, when possible.
Time frame: Baseline of randomized controlled trial (RCT) Visit 1 (Day 1) up to Visit 15 (Day 739) in the OLE
Number of Participants With Clinically Significant Changes in the Vital Sign Values of Pulse Rate From the Baseline at Any Time Post-dose
Potentially clinically significant vital sign values of pulse rate were defined as pulse rate change: \< -10 or \> 10 beats per minute. Vital sign measurements were taken in a sitting position at rest for 5 minutes.
Time frame: Baseline of randomized controlled trial (RCT) Visit 1 (Day 1) up to Visit 15 (Day 739) in the OLE
Number of Participants With Clinically Significant Percent Change in Body Weight From the Baseline at Any Time Post-dose
Clinically significant body weight changes were defined as the percent change in body weight (≤7% change or ≥7% change).
Time frame: Baseline of randomized controlled trial (RCT) Visit 1 (Day 1) up to Visit 14 (Day 729) in the OLE
Number of Participants With At Least One Post Open Label Extension Baseline Flagged ECG Result
Electrocardiogram assessments were performed for QTcB and QTcF \>450 msec, \>480 msec, and \>500 msec. QTcB = corrected QT interval with Bazette correction. QTcF = QTc corrected by Fridericia.
Time frame: Visit 4 (Day 29) up to Visit 15 (Day 739) in the OLE
Number of Participants With Any Changes In Menstruation Cycle at Any Time Post-dose
Participants were evaluated for any changes to typical menstrual cycles, duration of menstrual cycles, and typical strength of the menstrual cycles during the study.
Time frame: Baseline of randomized controlled trial (RCT) Visit 1 (Day 1) up to Visit 14 (Day 729) in the OLE
Number of Participants With Suicidal Ideation or Behavior at the Baseline and at Any Time Post-dose
Suicidal ideation and behavior was assessed by the investigator via a clinical interview with the caregiver. The questionnaire included following questions: Has the child expressed any wish to be dead?, Has the child made any suicide attempts?, Has the child shown any non-suicidal self-injurious behavior? The responses were recorded as Yes/No.
Time frame: Baseline of randomized controlled trial (RCT) Visit 1 (Day 1) up to Visit 14 (Day 729) in the OLE
Mean Change From Baseline in Insulin-like Growth Factor-1 (IGF-1) Levels at End of Treatment
Blood samples were collected to assess changes in serum IGF-1 levels. A negative mean change from baseline indicates a reduction in IGF-1 levels.
Time frame: Baseline of randomized controlled trial (RCT) Visit 1 (Day 1) up to Visit 14 (Day 729) in the OLE
Number of Participants With Changes in Tanner Staging at the Baseline and at End of Treatment
Pubic hair growth and breast development of all adolescents were assessed by the investigator or caregiver using Tanner Staging categorization from 1 to 5. Stage 1- No glandular tissue; areola follows skin contours of chest; No pubic hair Stage 2- Breast bud forms; areola begins to widen; a small amount of long, downy hair with slight pigmentation on labia majora Stage 3- Breast begins to become more elevated and extends beyond borders of the areola, which continues to widen but remains in contour with surrounding breast; Hair becomes more coarse and curly and begins to extend laterally Stage 4- Increased breast size and elevation; areola and papilla form a secondary mound projecting from the contour of the surrounding breast; Adult-like hair quality, extending across pubis but sparing medial thighs Stage 5- Breast reaches final adult size; areola returns to the contour of the surrounding breast, with a projecting central papilla; Hair extends to medial surface of the thigh.
Time frame: Baseline of randomized controlled trial (RCT) Visit 1 (Day 1) up to Visit 14 (Day 729) in the OLE
Mean Change From Baseline in Rett Syndrome Behaviour Questionnaire (RSBQ) Overall Score at End of Treatment
RSBQ is a caregiver-completed questionnaire that assesses the overall condition (45 items) in individuals with Rett Syndrome. Each item is rated on a 3-point scale (0-2); 0 indicating an item that is "not true as far as you know," 1 indicating an item is "somewhat or sometimes true," and 2 indicating an item that is "very true or often true". " Item 31 ("Uses eye gaze to convey feelings, needs and wishes") is reverse-scored (0 indicating "very true or often true", 1 indicating "somewhat or sometimes true," and 2 indicating "not true as far as you know"). The total summed score ranges from 0 to 90, with higher scores representing greater severity. A negative mean change from baseline indicates an improvement in overall condition.
Time frame: Baseline of randomized controlled trial (RCT) Visit 1 (Day 1) up to Visit 14 (Day 729) in the OLE
Mean Clinical Global Impressions-Improvement (CGI-I) Continuous Score at End of Treatment
CGI-I is a 7-point scale that requires the clinician to assess whether a patient's condition has improved or worsened relative to a baseline state at the beginning of the intervention. This was rated as: 1 = very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 = minimally worse; 6 = much worse; or 7 = very much worse. The mean continuous CGI-I score (averaged from each treatment enrolled under protocol and under annex) at Visit 14 (Day 729) is being reported. Higher mean scores indicate worse condition.
Time frame: Visit 14 (Day 729) in the OLE
Mean Clinician Global Impressions - Severity Scale (CGI-S) Continuous Score at End of Treatment
CGI-S is a 7-point scale that requires the clinician to rate the severity of the participant's illness at the time of assessment relative to the clinician's experience with participants who had the same diagnosis. This was rated as: 1 = normal, not at all ill; 2 = borderline ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 =severely ill; or 7 = extremely ill. The mean continuous CGI-S score (averaged from each treatment enrolled under protocol and under annex) at Visit 14 (Day 729) is being reported. Higher scores indicate more severe disease.
Time frame: Visit 14 (Day 729) in the OLE
Mean Change From Baseline in Children's Sleep Habits Questionnaire (CSHQ) Total Score at End of Treatment
CSHQ is a caregiver-completed sleep screening instrument designed for school-aged children; which includes 33 items within 8 subscales:bedtime resistance (score range 6-18), sleep onset delay (range 1-3), sleep duration (range 3-9), sleep anxiety (range 4-12), night wakings (range 3-9), parasomnias (range 7-21), sleep-disordered breathing (range 3-9), daytime sleepiness (range 8-24). The 33 items range from 1 to 3, where 3="usually" (≥5 times/week), 2="sometimes" (2-4 times/week), and 1="rarely" (≤1 time/week); for items 31 and 32, 3=fall asleep, 2=very sleepy, 1=not sleepy. A score of 3 indicates greater severity; however, 6 items (1-Goes to bed at same time; 3-Falls asleep in own bed; 26-Wakes by himself; 2-Falls asleep in 20 minutes; 10-Sleeps the right amount; 11-Sleeps same amount each day) are reverse scored. The total summed score ranges from 33 to 99, with higher scores indicating disturbed sleep behavior. A negative mean change from baseline indicates improvement in sleep.
Time frame: Baseline of randomized controlled trial (RCT) Visit 1 (Day 1) up to Visit 14 (Day 729) in the OLE
Mean Change From Baseline in 9-item Motor Behavioral Assessment (MBA-9) Total Score at End of Treatment
MBA-9 is derived from the full MBA scale (37 Rett syndrome symptoms) by selecting the items deemed amenable to change and which reflected areas of meaningful clinical change. The MBA-9 includes 9 items (Regression of motor skills; Poor eye/social contact; Lack of sustained interest; Does not reach for objects or people; Chewing difficulties; Speech disturbance; Hand clumsiness; Dystonia; and Hypertonia/rigidity). For each item, the severity of current symptoms is rated by the investigator on a 5-point numerical scale ranging from 0 to 4 with higher scores representing greater severity (0 = normal or never; 1 = mild or rare; 2 = moderate or occasional; 3 = marked or frequent; 4 = very severe or constant). Total MBA-9 score was calculated by summing the scores of 9 different subscale items. The total summed score ranges from 0 to 36, with higher scores representing greater severity. A negative mean change from baseline indicates improvement in behavior.
Time frame: Baseline of randomized controlled trial (RCT) Visit 1 (Day 1) up to Visit 14 (Day 729) in the OLE
A total of 21 participants who had previously participated in the randomized, double-blind, placebo-controlled trial GWND18064 (NCT03848832) entered this open label extension study.
| Milestone | GWP42003-P |
|---|---|
| Started | 21 |
| Completed | 0 |
| Not completed | 21 |
| Withdrew: Withdrawal by parent/guardian | 3 |
| Withdrew: Adverse event | 1 |
| Withdrew: Death | 2 |
| Withdrew: Study terminated by sponsor | 4 |
| Withdrew: Sponsor request | 10 |
| Withdrew: Did not complete treatment period | 1 |
Adverse events (AEs) were defined as any new unfavorable/unintended signs/symptoms (including abnormal laboratory findings when relevant) or diagnosis or worsening of a pre-existing condition that occurs during the study. TEAEs were defined as the AEs that started or worsened in severity or seriousness following the first dose of GWP42003-P. A serious AE was defined as any AE that results in any of the following outcomes: death, life-threatening adverse experience, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or cancer, any other experience that suggests a significant hazard, contraindication, side effect or precaution that may require medical or surgical intervention to prevent one of the outcomes listed above, or an event that changes the risk/benefit ratio of the study.
| Participants | GWP42003-P |
|---|---|
| Any TEAE | 19 |
| Treatment-related TEAEs | 7 |
| TEAEs leading to discontinuation | 3 |
| Treatment-related TEAE leading to discontinuation | 1 |
| Serious TEAEs | 5 |
| Treatment-related serious TEAEs | 0 |
Treatment-emergent clinical parameters were defined as the following: Treatment-emergent alanine transferase (ALT) \> 3×upper limit of normal (ULN), \> 5×ULN and \> 8×ULN; Treatment-emergent aspartate aminotransferase (AST) \> 3×ULN, \> 5×ULN and \> 8×ULN; Treatment-emergent ALT or AST \> 3×ULN, \> 5×ULN and \> 8×ULN; Treatment-emergent ALT or AST \> 3×ULN and either bilirubin \> 2×ULN or international normalized ratio (INR) \> 1.5.
| Participants | GWP42003-P |
|---|---|
| Treatment-emergent ALT >3xULN | 1 |
| Treatment-emergent ALT >5xULN | 0 |
| Treatment-emergent ALT >8xULN | 0 |
| Treatment-emergent AST >3xULN | 0 |
| Treatment-emergent AST >5xULN | 0 |
| Treatment-emergent AST >8xULN | 0 |
| Treatment-emergent ALT or AST >3xULN | 1 |
| Treatment-emergent ALT or AST >5xULN | 0 |
| Treatment-emergent ALT or AST >8xULN | 0 |
| Treatment-emergent ALT or AST > 3×ULN and either bilirubin > 2×ULN or INR > 1.5 | 0 |
Potentially clinically significant vital sign values of blood pressure (BP) were defined as sitting systolic BP (mmHg) change: \< -20 or \> 20 mmHg and sitting diastolic BP change: \< -10 or \> 10 mmHg. Vital sign measurements were taken in a sitting position at rest for 5 minutes. Blood pressure readings were recorded using the same arm throughout the trial, when possible.
| Participants | GWP42003-P |
|---|---|
| Systolic BP Change <-20 mmHg, Baseline | 4 |
| Systolic BP Change <-20 mmHg, Day 29 | 2 |
| Systolic BP Change <-20 mmHg, Day 57 | 1 |
| Systolic BP Change <-20 mmHg, Day 85 | 1 |
| Systolic BP Change <-20 mmHg, Day 141 | 2 |
| Systolic BP Change <-20 mmHg, Day 197 | 2 |
| Systolic BP Change <-20 mmHg, Day 281 | 0 |
| Systolic BP Change <-20 mmHg, Day 365 | 0 |
| Systolic BP Change <-20 mmHg, End of Treatment (up to Day 729) | 1 |
| Systolic BP Change <-20 mmHg, Day 739 | 1 |
| Systolic BP Change >20 mmHg, Baseline | 1 |
| Systolic BP Change >20 mmHg, Day 29 | 1 |
| Systolic BP Change >20 mmHg, Day 57 | 3 |
| Systolic BP Change >20 mmHg, Day 85 | 2 |
| Systolic BP Change >20 mmHg, Day 141 | 0 |
| Systolic BP Change >20 mmHg, Day 197 | 0 |
| Systolic BP Change >20 mmHg, Day 281 | 0 |
| Systolic BP Change >20 mmHg, Day 365 | 0 |
| Systolic BP Change >20 mmHg, End of Treatment (up to Day 729) | 2 |
| Systolic BP Change >20 mmHg, Day 739 | 0 |
| Diastolic BP Change <-10 mmHg, Baseline | 7 |
| Diastolic BP Change <-10 mmHg, Day 29 | 4 |
| Diastolic BP Change <-10 mmHg, Day 57 | 4 |
| Diastolic BP Change <-10 mmHg, Day 85 | 2 |
| Diastolic BP Change <-10 mmHg, Day 141 | 3 |
| Diastolic BP Change <-10 mmHg, Day 197 | 3 |
| Diastolic BP Change <-10 mmHg, Day 281 | 0 |
| Diastolic BP Change <-10 mmHg, Day 365 | 0 |
| Diastolic BP Change <-10 mmHg, End of Treatment (up to Day 729) | 3 |
| Diastolic BP Change <-10 mmHg, Day 739 | 0 |
| Diastolic BP Change >10 mmHg, Baseline | 4 |
| Diastolic BP Change >10 mmHg, Day 29 | 9 |
| Diastolic BP Change >10 mmHg, Day 57 | 4 |
| Diastolic BP Change >10 mmHg, Day 85 | 4 |
| Diastolic BP Change >10 mmHg, Day 141 | 3 |
| Diastolic BP Change >10 mmHg, Day 197 | 1 |
| Diastolic BP Change >10 mmHg, Day 281 | 0 |
| Diastolic BP Change >10 mmHg, Day 365 | 0 |
| Diastolic BP Change >10 mmHg, End of Treatment (up to Day 729) | 5 |
| Diastolic BP Change >10 mmHg, Day 739 | 0 |
Potentially clinically significant vital sign values of pulse rate were defined as pulse rate change: \< -10 or \> 10 beats per minute. Vital sign measurements were taken in a sitting position at rest for 5 minutes.
| Participants | GWP42003-P |
|---|---|
| Pulse Rate Change <-10beats/min, Baseline | 9 |
| Pulse Rate Change <-10beats/min, Day 29 | 8 |
| Pulse Rate Change <-10beats/min, Day 57 | 7 |
| Pulse Rate Change <-10beats/min, Day 85 | 7 |
| Pulse Rate Change <-10beats/min, Day 141 | 2 |
| Pulse Rate Change <-10beats/min, Day 197 | 5 |
| Pulse Rate Change <-10beats/min, Day 281 | 1 |
| Pulse Rate Change <-10beats/min, Day 365 | 1 |
| Pulse Rate Change <-10beats/min, End of Treatment (up to Day 729) | 6 |
| Pulse Rate Change <-10beats/min, Day 739 | 0 |
| Pulse Rate Change >10beats/min, Baseline | 5 |
| Pulse Rate Change >10beats/min, Day 29 | 2 |
| Pulse Rate Change >10beats/min, Day 57 | 3 |
| Pulse Rate Change >10beats/min, Day 85 | 3 |
| Pulse Rate Change >10beats/min, Day 141 | 3 |
| Pulse Rate Change >10beats/min, Day 197 | 1 |
| Pulse Rate Change >10beats/min, Day 281 | 0 |
| Pulse Rate Change >10beats/min, Day 365 | 0 |
| Pulse Rate Change >10beats/min, End of Treatment (up to Day 729) | 4 |
| Pulse Rate Change >10beats/min, Day 739 | 2 |
Clinically significant body weight changes were defined as the percent change in body weight (≤7% change or ≥7% change).
| Participants | GWP42003-P |
|---|---|
| Weight Percent Change ≤7%, Baseline | 1 |
| Weight Percent Change ≤7%, End of Treatment (up to Day 729) | 1 |
| Weight Percent Change ≥7%, Baseline | 8 |
| Weight Percent Change ≥7%, End of Treatment (up to Day 729) | 10 |
Electrocardiogram assessments were performed for QTcB and QTcF \>450 msec, \>480 msec, and \>500 msec. QTcB = corrected QT interval with Bazette correction. QTcF = QTc corrected by Fridericia.
| Participants | GWP42003-P |
|---|---|
| QTcB Interval, Aggregate > 450 msec, Day 29 | 4 |
| QTcB Interval, Aggregate > 450 msec, Day 57 | 0 |
| QTcB Interval, Aggregate > 450 msec, Day 85 | 4 |
| QTcB Interval, Aggregate > 450 msec, Day 141 | 0 |
| QTcB Interval, Aggregate > 450 msec, Day 197 | 0 |
| QTcB Interval, Aggregate > 450 msec, Day 365 | 0 |
| QTcB Interval, Aggregate > 450 msec, End of Treatment (up to Day 729) | 4 |
| QTcB Interval, Aggregate > 450 msec, Day 739 | 0 |
| QTcB Interval, Aggregate > 480 msec, Day 29 | 0 |
| QTcB Interval, Aggregate > 480 msec, Day 57 | 0 |
| QTcB Interval, Aggregate > 480 msec, Day 85 | 1 |
| QTcB Interval, Aggregate > 480 msec, Day 141 | 0 |
| QTcB Interval, Aggregate > 480 msec, Day 197 | 0 |
| QTcB Interval, Aggregate > 480 msec, Day 365 | 0 |
| QTcB Interval, Aggregate > 480 msec, End of Treatment (up to Day 729) | 1 |
| QTcB Interval, Aggregate > 480 msec, Day 739 | 0 |
| QTcB Interval, Aggregate > 500 msec, Day 29 | 0 |
| QTcB Interval, Aggregate > 500 msec, Day 57 | 0 |
| QTcB Interval, Aggregate > 500 msec, Day 85 | 0 |
| QTcB Interval, Aggregate > 500 msec, Day 141 | 0 |
| QTcB Interval, Aggregate > 500 msec, Day 197 | 0 |
| QTcB Interval, Aggregate > 500 msec, Day 365 | 0 |
| QTcB Interval, Aggregate > 500 msec, End of Treatment (up to Day 729) | 0 |
| QTcB Interval, Aggregate > 500 msec, Day 739 | 0 |
| QTcF Interval, Aggregate > 450 msec, Day 29 | 0 |
| QTcF Interval, Aggregate > 450 msec, Day 57 | 0 |
| QTcF Interval, Aggregate > 450 msec, Day 85 | 1 |
| QTcF Interval, Aggregate > 450 msec, Day 141 | 0 |
| QTcF Interval, Aggregate > 450 msec, Day 197 | 0 |
| QTcF Interval, Aggregate > 450 msec, Day 365 | 0 |
| QTcF Interval, Aggregate > 450 msec, End of Treatment (up to Day 729) | 0 |
| QTcF Interval, Aggregate > 450 msec, Day 739 | 0 |
| QTcF Interval, Aggregate > 480 msec, Day 29 | 0 |
| QTcF Interval, Aggregate > 480 msec, Day 57 | 0 |
| QTcF Interval, Aggregate > 480 msec, Day 85 | 0 |
| QTcF Interval, Aggregate > 480 msec, Day 141 | 0 |
| QTcF Interval, Aggregate > 480 msec, Day 197 | 0 |
| QTcF Interval, Aggregate > 480 msec, Day 365 | 0 |
| QTcF Interval, Aggregate > 480 msec, End of Treatment (up to Day 729) | 0 |
| QTcF Interval, Aggregate > 480 msec, Day 739 | 0 |
| QTcF Interval, Aggregate > 500 msec, Day 29 | 0 |
| QTcF Interval, Aggregate > 500 msec, Day 57 | 0 |
| QTcF Interval, Aggregate > 500 msec, Day 85 | 0 |
| QTcF Interval, Aggregate > 500 msec, Day 141 | 0 |
| QTcF Interval, Aggregate > 500 msec, Day 197 | 0 |
| QTcF Interval, Aggregate > 500 msec, Day 365 | 0 |
| QTcF Interval, Aggregate > 500 msec, End of Treatment (up to Day 729) | 0 |
| QTcF Interval, Aggregate > 500 msec, Day 739 | 0 |
Participants were evaluated for any changes to typical menstrual cycles, duration of menstrual cycles, and typical strength of the menstrual cycles during the study.
| Participants | GWP42003-P |
|---|---|
| Any change to typical cycle, Yes; Day 1 | 1 |
| Any change to typical cycle, No; Day 1 | 1 |
| Any change to typical cycle; Day 1 Unknown/Missing | 19 |
| Typical duration of menstruation cycle, <3 days; Day 1 | 0 |
| Typical duration of menstruation cycle, 3-7 days; Day 1 | 1 |
| Typical duration of menstruation cycle, >7 days; Day 1 | 0 |
| Typical duration of menstruation cycle; Day 1 Unknown/Missing | 20 |
| Typical strength of menstruation cycle, Light; Day 1 | 1 |
| Typical strength of menstruation cycle, Moderate; Day 1 | 0 |
| Typical strength of menstruation cycle, Heavy; Day 1 | 0 |
| Typical strength of menstruation cycle, Other; Day 1 | 0 |
| Typical strength of menstruation cycle; Day 1 Unknown/Missing | 20 |
| Any change to typical cycle, Yes; End of Treatment (up to Day 729) | 3 |
| Any change to typical cycle, No; End of Treatment (up to Day 729) | 3 |
| Any change to typical cycle; End of Treatment (up to Day 729) Unknown/Missing | 12 |
| Typical duration of menstruation cycle, <3 days; End of Treatment (up to Day 729) | 0 |
| Typical duration of menstruation cycle, 3-7 days; End of Treatment (up to Day 729) | 3 |
| Typical duration of menstruation cycle, >7 days; End of Treatment (up to Day 729) | 0 |
| Typical duration of menstruation cycle; End of Treatment (up to Day 729) Unknown/Missing | 15 |
| Typical strength of menstruation cycle, Light; End of Treatment (up to Day 729) | 1 |
| Typical strength of menstruation cycle, Heavy; End of Treatment (up to Day 729) | 2 |
| Typical strength of menstruation cycle, Moderate; End of Treatment (up to Day 729) | 0 |
| Typical strength of menstruation cycle, Other; End of Treatment (up to Day 729) | 0 |
| Typical strength of menstruation cycle; End of Treatment (up to Day 729) Unknown/Missing | 15 |
Suicidal ideation and behavior was assessed by the investigator via a clinical interview with the caregiver. The questionnaire included following questions: Has the child expressed any wish to be dead?, Has the child made any suicide attempts?, Has the child shown any non-suicidal self-injurious behavior? The responses were recorded as Yes/No.
| Participants | GWP42003-P |
|---|---|
| Has the child expressed any wish to be dead? Yes, Baseline | 0 |
| Has the child expressed any wish to be dead? No, Baseline | 16 |
| Has the child expressed any wish to be dead? Unknown/Missing, Baseline | 5 |
| Has the child expressed any wish to be dead? Yes, End of Treatment (up to Day 729) | 0 |
| Has the child expressed any wish to be dead? No, End of Treatment (up to Day 729) | 18 |
| Has the child made any suicide attempts? Yes, Baseline | 0 |
| Has the child made any suicide attempts? No, Baseline | 16 |
| Has the child made any suicide attempts? Unknown/Missing, Baseline | 5 |
| Has the child made any suicide attempts? Yes, End of Treatment (up to Day 729) | 0 |
| Has the child made any suicide attempts? No, End of Treatment (up to Day 729) | 18 |
| Has the child shown any non-suicidal self-injurious behavior? Yes, Baseline | 0 |
| Has the child shown any non-suicidal self-injurious behavior? Yes, usual behavior, Baseline | 3 |
| Has the child shown any non-suicidal self-injurious behavior? Yes, worsening behavior, Baseline | 0 |
| Has the child shown any non-suicidal self-injurious behavior? No, Baseline | 13 |
| Has the child shown any non-suicidal self-injurious behavior? Unknown/Missing, Baseline | 5 |
| Has the child shown any non-suicidal self-injurious behavior? Yes, End of Treatment (up to Day 729) | 0 |
| Has child shown any non-suicidal self-injurious behavior? Yes, usual behavior, EOT (up to Day 729) | 4 |
| Has child shown any non-suicidal self-injurious behavior? Yes, worse behavior, EOT (up to Day 729) | 0 |
| Has child shown any non-suicidal self-injurious behavior? No, End of Treatment (up to Day 729) | 14 |
Blood samples were collected to assess changes in serum IGF-1 levels. A negative mean change from baseline indicates a reduction in IGF-1 levels.
| units on a scale | GWP42003-P |
|---|---|
| Mean Change From Baseline in Insulin-like Growth Factor-1 (IGF-1) Levels at End of Treatment | -41.1 ± 100.77 |
Pubic hair growth and breast development of all adolescents were assessed by the investigator or caregiver using Tanner Staging categorization from 1 to 5. Stage 1- No glandular tissue; areola follows skin contours of chest; No pubic hair Stage 2- Breast bud forms; areola begins to widen; a small amount of long, downy hair with slight pigmentation on labia majora Stage 3- Breast begins to become more elevated and extends beyond borders of the areola, which continues to widen but remains in contour with surrounding breast; Hair becomes more coarse and curly and begins to extend laterally Stage 4- Increased breast size and elevation; areola and papilla form a secondary mound projecting from the contour of the surrounding breast; Adult-like hair quality, extending across pubis but sparing medial thighs Stage 5- Breast reaches final adult size; areola returns to the contour of the surrounding breast, with a projecting central papilla; Hair extends to medial surface of the thigh.
| Participants | GWP42003-P |
|---|---|
| Baseline, Tanner Stage 1 | 6 |
| Baseline, Tanner Stage 2 | 3 |
| Baseline, Tanner Stage 3 | 1 |
| Baseline, Tanner Stage 4 | 2 |
| Baseline, Tanner Stage 5 | 4 |
| Baseline, Tanner Stage Missing | 5 |
| End of Treatment (up to Day 729), Tanner Stage 1 | 4 |
| End of Treatment (up to Day 729), Tanner Stage 2 | 2 |
| End of Treatment (up to Day 729), Tanner Stage 3 | 1 |
| End of Treatment (up to Day 729), Tanner Stage 4 | 3 |
| End of Treatment (up to Day 729), Tanner Stage 5 | 3 |
| End of Treatment (up to Day 729), Tanner Stage Missing | 5 |
RSBQ is a caregiver-completed questionnaire that assesses the overall condition (45 items) in individuals with Rett Syndrome. Each item is rated on a 3-point scale (0-2); 0 indicating an item that is "not true as far as you know," 1 indicating an item is "somewhat or sometimes true," and 2 indicating an item that is "very true or often true". " Item 31 ("Uses eye gaze to convey feelings, needs and wishes") is reverse-scored (0 indicating "very true or often true", 1 indicating "somewhat or sometimes true," and 2 indicating "not true as far as you know"). The total summed score ranges from 0 to 90, with higher scores representing greater severity. A negative mean change from baseline indicates an improvement in overall condition.
| units on a scale | GWP42003-P |
|---|---|
| Mean Change From Baseline in Rett Syndrome Behaviour Questionnaire (RSBQ) Overall Score at End of Treatment | -7.4 ± 14.93 |
CGI-I is a 7-point scale that requires the clinician to assess whether a patient's condition has improved or worsened relative to a baseline state at the beginning of the intervention. This was rated as: 1 = very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 = minimally worse; 6 = much worse; or 7 = very much worse. The mean continuous CGI-I score (averaged from each treatment enrolled under protocol and under annex) at Visit 14 (Day 729) is being reported. Higher mean scores indicate worse condition.
| score on a scale | GWP42003-P |
|---|---|
| Mean Clinical Global Impressions-Improvement (CGI-I) Continuous Score at End of Treatment | 3.3 ± 1.15 |
CGI-S is a 7-point scale that requires the clinician to rate the severity of the participant's illness at the time of assessment relative to the clinician's experience with participants who had the same diagnosis. This was rated as: 1 = normal, not at all ill; 2 = borderline ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 =severely ill; or 7 = extremely ill. The mean continuous CGI-S score (averaged from each treatment enrolled under protocol and under annex) at Visit 14 (Day 729) is being reported. Higher scores indicate more severe disease.
| score on a scale | GWP42003-P |
|---|---|
| Mean Clinician Global Impressions - Severity Scale (CGI-S) Continuous Score at End of Treatment | 4.3 ± 0.96 |
CSHQ is a caregiver-completed sleep screening instrument designed for school-aged children; which includes 33 items within 8 subscales:bedtime resistance (score range 6-18), sleep onset delay (range 1-3), sleep duration (range 3-9), sleep anxiety (range 4-12), night wakings (range 3-9), parasomnias (range 7-21), sleep-disordered breathing (range 3-9), daytime sleepiness (range 8-24). The 33 items range from 1 to 3, where 3="usually" (≥5 times/week), 2="sometimes" (2-4 times/week), and 1="rarely" (≤1 time/week); for items 31 and 32, 3=fall asleep, 2=very sleepy, 1=not sleepy. A score of 3 indicates greater severity; however, 6 items (1-Goes to bed at same time; 3-Falls asleep in own bed; 26-Wakes by himself; 2-Falls asleep in 20 minutes; 10-Sleeps the right amount; 11-Sleeps same amount each day) are reverse scored. The total summed score ranges from 33 to 99, with higher scores indicating disturbed sleep behavior. A negative mean change from baseline indicates improvement in sleep.
| units on a scale | GWP42003-P |
|---|---|
| Mean Change From Baseline in Children's Sleep Habits Questionnaire (CSHQ) Total Score at End of Treatment | -3.0 ± 6.87 |
MBA-9 is derived from the full MBA scale (37 Rett syndrome symptoms) by selecting the items deemed amenable to change and which reflected areas of meaningful clinical change. The MBA-9 includes 9 items (Regression of motor skills; Poor eye/social contact; Lack of sustained interest; Does not reach for objects or people; Chewing difficulties; Speech disturbance; Hand clumsiness; Dystonia; and Hypertonia/rigidity). For each item, the severity of current symptoms is rated by the investigator on a 5-point numerical scale ranging from 0 to 4 with higher scores representing greater severity (0 = normal or never; 1 = mild or rare; 2 = moderate or occasional; 3 = marked or frequent; 4 = very severe or constant). Total MBA-9 score was calculated by summing the scores of 9 different subscale items. The total summed score ranges from 0 to 36, with higher scores representing greater severity. A negative mean change from baseline indicates improvement in behavior.
| units on a scale | GWP42003-P |
|---|---|
| Mean Change From Baseline in 9-item Motor Behavioral Assessment (MBA-9) Total Score at End of Treatment | 0.7 ± 5.19 |
Collected over Adverse event data were collected from baseline of randomized controlled trial (RCT) Visit 1 (Day 1) up to Visit 16 (Day 767) in the OLE.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| GWP42003-P | 2/21 (9.5%) | 5/21 (23.8%) | 19/21 (90.5%) |
| Event | GWP42003-P |
|---|---|
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 2/21 |
| Rett SyndromeCongenital, familial and genetic disorders | 1/21 |
| COVID-19Infections and infestations | 1/21 |
| Lower respiratory tract infectionInfections and infestations | 1/21 |
| Postoperative wound infectionInfections and infestations | 1/21 |
| Generalised tonic-clonic seizureNervous system disorders | 1/21 |
| Status epilepticusNervous system disorders | 1/21 |
| Respiratory arrestRespiratory, thoracic and mediastinal disorders | 1/21 |
| Event | GWP42003-P |
|---|---|
| VomitingGastrointestinal disorders | 7/21 |
| DiarrhoeaGastrointestinal disorders | 4/21 |
| PyrexiaGeneral disorders | 4/21 |
| Upper respiratory tract infectionInfections and infestations | 3/21 |
| Monocyte count decreasedInvestigations | 3/21 |
| Decreased appetiteMetabolism and nutrition disorders | 3/21 |
| SeizureNervous system disorders | 3/21 |
| IrritabilityPsychiatric disorders | 3/21 |
| NeutropeniaBlood and lymphatic system disorders | 2/21 |
| Otitis mediaInfections and infestations | 2/21 |
Baseline characteristics were assessed in the Safety Analysis Set which was defined as all participants who received at least one dose of GWP42003-P in the study.
| Age, Continuous(years) | GWP42003-P |
|---|---|
| Mean | 10.2 ± 5.59 |
| Age, Customized(Participants) | GWP42003-P |
|---|---|
| 2-5 years | 6 |
| 6-12 years | 9 |
| 13-19 years | 6 |
| Sex: Female, Male(Participants) | GWP42003-P |
|---|---|
| Female | 21 |
| Male | 0 |
| Ethnicity (NIH/OMB)(Participants) | GWP42003-P |
|---|---|
| Hispanic or Latino | 1 |
| Not Hispanic or Latino | 20 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | GWP42003-P |
|---|---|
| American Indian or Alaska Native | 1 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 20 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Feb 2020 to primary completion in Jun 2021, 15 months.
Results were first posted in Aug 2022, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cannabidiol